Gehanno P
Service ORL, Groupe Hospitalier Bichat, Claude-Bernard, Paris, France.
Pathol Biol (Paris). 1995 Jun;43(6):530-3.
If the demonstration of the interest to treat beta-haemolytic streptococcal pharyngitis is not to be done, the recommended antibiotics, most of the time, display the drawback of a treatment with one to three intakes daily for 10 days. The azithromycin, with its numerous properties, allows for the required treatment duration, to decrease the intakes number, thus facilitating the compliance. Its in vitro activity is very good on streptococci with a MIC90 of 0.06 mg/l. Its in vivo activity in animal, with experimental Streptococcus pyogenes infection models is identical to the amoxicillin activity, and better than those of other tested macrolides. One of the major characteristics of azithromycin in man is its most peculiar pharmacokinetic with an extended half life and very high tonsillar concentrations, for at least 10 days after the administration of the product at the 1.5 g dose regimen over 3 days. In streptococcal acute tonsillitis clinical studies, with a 1.5 g dose regimen over 5 days, clinical results and bacterial eradication are identical to those obtained in the Penicillin V groups. This administration facility should greatly improve the treatment compliance and lower the risks of a prematurely discontinued treatment.
如果不打算证实治疗β溶血性链球菌性咽炎的益处，大多数情况下，推荐使用的抗生素存在每天需服药1至3次、持续10天的治疗弊端。阿奇霉素具有多种特性，可实现所需的治疗疗程，减少服药次数，从而提高依从性。它对链球菌的体外活性非常好，其MIC90为0.06mg/l。在动物实验性化脓性链球菌感染模型中，它的体内活性与阿莫西林相同，且优于其他受试大环内酯类药物。阿奇霉素在人体内的一个主要特性是其独特的药代动力学，半衰期延长，扁桃体浓度非常高，在3天内给予1.5g剂量方案的产品后，至少10天内保持高浓度。在链球菌性急性扁桃体炎的临床研究中，采用5天1.5g剂量方案，临床结果和细菌清除情况与青霉素V组相同。这种给药便利性应能极大地提高治疗依从性，并降低过早停药的风险。
